Explicyte Immuno-Oncology

New Paper in #MolecularCancer! In this study led by Prof. Italiano Antoine (Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers), 49 patients with advanced gastric cancer were treated with Avelumab (anti-PD/PD-L1) in combination with Regorafenib (anti-angiogenic drug). Despite encouraging efficacy results, a significant subset of patients did not respond. Explicyte Immuno-Oncology explored resistance mechanisms in specimens from the REGOMUNE & REGONIVO trials, using sequentially #SpatialTranscriptomics, #DigitalPathology, #PlasmaProteomics, highlighting that non-responding patients feature: > In the #ImmuneCompartment: CD163 gene overexpression, alongside an enrichment in M2 #macrophages (significant increase in M2/M1 ratio) > In #TumorCells: strong upregulation of S100A10 - a protein involved in macrophage chemotaxis > In #PlasmaSamples: Upregulation of cytokines involved in macrophage infiltration, such a CSF-1, IL-4, IL-8, and TWEAK. Altogether, this paper highlights the central role of #M2macrophages in the #resistance to anti-PD-1/PD-L1 #immunotherapy combined with #antiangiogenic therapy in gastric cancers, and provides perspectives for novel diagnostic and therapeutic approaches. Read paper: https://lnkd.in/dd2SSkqk Contributors : Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola-Jade Palmieri, Jean-Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine Bellera, Antoine Adenis, Carlos Gomez-Roca, CASSIER Philippe, Antoine Hollebecque, Coralie Cantarel, Michèle Kind, Isabelle Soubeyran, Lucile Vanhersecke, Alban Bessede, PhD CHU de Brest, BPH Bordeaux Population Health - Centre de recherche sur la santé des populations de Bordeaux, IRCM - Institut de Recherche en Cancérologie de Montpellier, IUCT-Oncopole, Centre Léon Bérard, Olink Proteomics, NanoString Technologies, Inc., Akoya Biosciences, Inc.

#NewPaper in the Journal of Hematology & Oncology! Full text: https://lnkd.in/dRY3Jt-K In this retrospective study led by Prof. Italiano Antoine (Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers) based on the NEOSARCOMICS trial, we investigated whether #microenvironment features of #UndifferentiatedPleomorphicSarcomas (UPS) – an aggressive subtype of soft tissue sarcoma – could predict response to #neoadjuvant anthracycline-based #chemotherapy. #MicroenvironmentFeatures & prognosis without #NeoadjuvantTherapy:  We applied a multiplexed immunohistofluorescence (mIHF) panel on tumor samples from 47 patients with UPS who underwent surgical resection. We found that patients with poor survival had fewer infiltrated immune cells (especially CD8+ cells and M1 macrophages), while patients with better overall survival tended to feature high tumor infiltration. #MicroenvironmentFeatures & #response to #NeoadjuvantTherapy:  We then analyzed the gene expression of baseline samples from 24 patients with resectable UPS, who were treated with neoadjuvant chemotherapy. We found that a good response was associated with a high proliferation and low immune infiltration phenotype. This finding was confirmed with the multiplex mIHF panel: patients who poorly respond to neoadjuvant therapy feature high immune infiltration. #PlasmaProteomics confirmed the upregulation of cell cycle pathways in low immune infiltration patients. These results suggest that immune infiltration status can serve to stratify UPS patients before surgical resection. Patients with high immune infiltration benefit from a better prognosis from the start and may respond poorly to chemotherapy. However, neoadjuvant therapy may improve the prognosis of immune-low UPS patients. Thanks to all contributors! Jean-Philippe Guégan, Nathan El Ghazzi, Julien Vibert (李满山), Christophe REY, Lucile Vanhersecke, Jean Michel Coindre, Maud Toulmonde, Mariella SPALATO CERUSO, Florent Peyraud, Alban Bessede, PhD, Italiano Antoine, Université de Bordeaux, CHU de Clermont-Ferrand. Learn more about Explicyte Immuno-Oncology's services in translational research: https://lnkd.in/daWg_DcS

Explicyte is the⚡first #ImmunoOncology #CRO in #Europe⚡equipped with 10x Genomics #Xenium platform for #SingleCell #SpatialTranscriptomics! Training by the 10x team started! Why is it exciting? Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology: “For our translational and data science team, the Xenium platform opens unexplored avenues for analyzing tumors and their microenvironment in response to various cancer modalities, including immunotherapies. For our sponsors, gaining a deep understanding of the gene expression profiles and spatial distribution of individual cells within a tumor specimen can provide unique insights into tumor biology and the mechanisms at play in anti-cancer response or resistance to treatment. It creates opportunities to identify new therapeutic targets and predictive biomarkers for cancer patients. And as a scientist, I’m eager to watch tumor cells, immune cells, and cancer-associated fibroblasts with the Xenium eye, and to witness the single-cell architecture of immune infiltrates and tertiary lymphoid structures. It’s truly exciting to enter the world of single-cell spatial transcriptomics."   About the 10x Xenium platform: > Compatible with standard tumor specimens (frozen & FFPE) > TME architecture is visualized at subcellular level with a 5000-gene panel > Single-cell analysis & segmentation with AI-driven algorithm 

#Sarcoma #Microenvironment #Immunotherapy I attended yesterday with colleagues from Explicyte Immuno-Oncology the 2nd Symposium of the RHU CONDOR programme in Bordeaux. Insightful talks and discussions with world-class experts in sarcoma immunotherapy: > Sandra D'Angelo, MSKCC > John Stagg, Univ. Montreal > Wolf Hervé Fridman, Centre de Recherche des Cordeliers > Alessandra Merlini, Univ. Turin > Stephen Hunt, MTR, MD, PhD, FSIR, UPenn > Lucile Vanhersecke, Institut Bergonié > Thibaut Brugat, DOMAIN Therapeutics > Halin Bareke, Institute for Health Research IdiPAZ-CNIO > Yann Rodriguez, Owkin > And more... Thanks Italiano Antoine for setting up this meeting ! Paul Marteau, Imane Nafia, Jean-Philippe Guégan, Loic Cerf

#Hiring #PostDoc #Translational #Research #ImmunoOncology #Bordeaux #France Apply here: https://lnkd.in/dpbepdSb   🔬 What We’re Looking For: > Expertise in omics data analysis (transcriptomics: bulk, spatial, single-cell) > High proficiency in image analysis from multiplexed IHC/IHF > Ability to work autonomously and drive impactful research projects 📚 Your Mission: Make groundbreaking discoveries and contribute to high-impact scientific publications (check our past papers: https://lnkd.in/du-9cw76) If you’re ready to take on this challenge and make a difference in the fight against cancer, we’d love to hear from you! Learn more about Explicyte and apply: https://lnkd.in/dpbepdSb

LAST DAYS TO REGISTER! #Webinar #TLS #Modulation in #Cancer #Immunotherapy on Sept 5th. Don't miss out - register now: https://lnkd.in/dPg56QhY Talk #1 : Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed? by Tullia Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh Talk #2: Predictive role of TLS in cancer immunotherapy: Current insights and perspectives by Pr. Italiano Antoine, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers This 45-minute webinar session will be hosted by Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology. Learn more about Explicyte's in-house panels & expertise in TLS detection and evaluation for cancer immunotherapy: https://lnkd.in/dvuMa4-f

#TLS #Modulation in #Cancer #Immunotherapy - Register for this webinar on September 5th : https://lnkd.in/dPg56QhY Talk #1 : Tertiary lymphoid structures as modulators of anti-tumor immunity: what do we know and where are we headed? by Tullia Bruno, PhD - UPMC Hillman Cancer Center / University of Pittsburgh Talk #2: Predictive role of TLS for cancer immunotherapy: current insights and perspectives by Pr. Italiano Antoine, MD, PhD - Institut Bergonié & Gustave Roussy Comprehensive Cancer Centers This 45-min webinar session will be hosted by Alban Bessede, PhD, CEO of Explicyte Immuno-Oncology. Learn about Explicyte's in-house panels & expertise in TLS detection and evaluation for cancer immunotherapy: https://lnkd.in/dvuMa4-f

#SarcomaAwarenessMonth From “cold” to “hot” soft-tissue sarcomas – focus on a key 2024 paper in Molecular Cancer in collaboration with the Institut Bergonié Comprehensive Cancer Center In soft tissue sarcomas, the presence of tertiary lymphoid structures (#TLS) is known to increase sensitivity to immune checkpoint inhibitors. In a clinical trial conducted at the Institut Bergonié, Prof. Italiano Antoine and colleagues studied the combination of an #oncolyticvirus and metronomic chemotherapy with the aim of remodeling the tumor microenvironment of patients with TLS-negative soft-tissue #sarcoma, thereby improving their sensitivity to the #PDL1 inhibitor Avelumab. As part of this study, tumor biopsies and plasma samples were processed by Explicyte teams, for both staining and Olink-based proteomics respectively. Our results confirm that intratumoral administration of the oncolytic virus JX-584 can alter the immune landscape of the tumor microenvironment, potentially converting cold tumors into immunogenic tumors. Read the paper: https://lnkd.in/drmnvMcD Congrats to all contributors: Maud Toulmonde, Jean-Philippe Guégan, Mariella SPALATO CERUSO Florent Peyraud Michèle Kind Lucile Vanhersecke François Le Loarer Raul Perret Coralie Cantarel Carine Bellera Alban Bessede, PhD

I will be fully supporting Grégory LE BRAS from September 8 to 14! 🏃♂️ An Anesthesia Nurse at the Institut Bergonié, he has decided to run the #TORdesGéants [a 330 Km ultra-trail in the Alps] in support of sarcoma research. I wish him the best for his last month of physical preparation, and I invite you to join us in September to cheer him on and donate to the “La Course du Petit Prince” Association: https://lnkd.in/ds-FZgti. The funds raised during the race will be donated to RHU CONDOR, a research program I am leading for the development of new immunotherapies against sarcomas. Learn more about RHU: https://lnkd.in/etHhSfU3 #Research #Health #Sport #Solidarity #Sarcomas

On sera à fond derrière Grégory LE BRAS du 8 au 14 septembre ! Infirmier Anesthésiste à l'Institut Bergonié, il a décidé de courir le #TORdesGéants [ultra-trail de 330 Km dans les Alpes] au profit de la recherche sur les sarcomes. Nous lui souhaitons le meilleur pour son dernier mois de préparation physique, et nous vous donnons RDV en septembre pour l'encourager et transmettre vos dons à l'Association "La Course du Petit Prince" : https://lnkd.in/ds-FZgti. Les fonds levés pendant la course seront reversés au RHU CONDOR, un programme de recherche dirigé par le Pr Italiano Antoine pour le développement de nouvelles immunothérapies contre les sarcomes. En savoir plus sur le RHU: https://lnkd.in/etHhSfU3